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osting by EAbstract Purpose: To evaluate the clinical efﬁcacy and safety of controlled contact transscleral
diode laser Cyclophotocoagulation (COCO) procedure in reducing the Intraocular Pressure
(IOP) among patients with refractory glaucoma.
Methods: Thirty two patients (35 eyes) with refractory glaucoma in prospective clinical studies
were treated with trans-sclera diode laser in a controlled manner. The energy power used was
5 W in adults and 3 W in children, exposure time was 0.5 s, a total of 16 shots were applied over
ciliary body and four shots in each quadrant. Pre and postoperative IOP were measured at different
postoperative visits. Snellen visual acuity, the number of anti-glaucoma medications and associated
complications were also recorded. Student T test was used to compare the pre and post intervention
IOPs, while Wilcoxon Signed Ranks test was used, to detect signiﬁcance change in medication
dependency.
Results: The mean (SD) follow up time was 80.2(±9.6) months, range (36–84) m, where the
mean IOP was signiﬁcantly reduced from 35.1 mm Hg (±10.7) before intervention to 18.8 mm Hg
(±7.3) after intervention, in the ﬁnal visit (P< 0.0001). Complete success was achieved in seven
eyes (20%), 22 eyes (62.8%) showed qualiﬁed successes and complete failure was reported in six
eyes (17.1%). The overall success rate was 82.8% (95% CI: 70.4–95.3). Visual acuity improveding Abdul Aziz University
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10 E.A. Osman et al.in three eyes (8.5%), no change took place in 27 eyes (77.1%) and decreased in ﬁve eyes (14.2%).
The number of anti-glaucoma medications has signiﬁcantly changed between pre and post interven-
tion (P< 0.0001). No cases of hypotony, phthisis bulbi or sympathetic ophthalmia were reported.
Conclusion: Controlled COCO is a simple procedure, safe with minimal complications and fewer
side effects.
ª 2009 King Saud University. All rights reserved.Table 1 Types of glaucoma etiologies.1. Introduction
Contact transscleral diode laser Cyclophotocoagulation
(COCO) has been established as a relatively safe and effective
treatment for uncontrolled glaucoma in adult and pediatric pa-
tients (Hennis and Stewart, 1992; Hawkins and Stewart, 1993;
Kosoko et al., 1996; Brancato et al., 1995; Threlkeld and John-
son, 1999; Egbert et al., 2001; Mistlberger et al., 2001). This is
compared to ND:YAG laser COCO and cyclocryotherapy,
that carry risk of hypotony and phthisis bulbi (Benson and
Nelson, 1990; Brindley and Shields, 1968; Ulbig et al., 1995).
Cyclodestructive procedures – contrary to ﬁltering glaucoma
surgery – and tube surgery lower the IOP by reducing the in-
ﬂow as a result of destruction of ciliary body. The high rate
of complications includes phthisis bulbi, visual loss, and an
unpredictable degree of IOP reduction. These procedures are
usually convenient to patients with refractory glaucomas
where trabeculectomy or tube shunt operations have failed, pa-
tients with no visual potential, in need of pain relief, patients
with complicated glaucoma and conjunctival scarring due to
previous surgery.
Destruction of ciliary body has been introduced in the
treatment of glaucoma since 1930 (Vogt, 1936). Cyclocryother-
apy was introduced by Bietti in 1950 (Benson and Nelson,
1990; Brindley and Shields, 1968; Bietti, 1950), with less
destructive effect than cyclodiathermy, but still having its com-
plications of postoperative severe pain hypotony, visual loss
and phthisis bulbi.
Cyclophotocoagulation was ﬁrst proposed by Weekers and
Coworker in 1961 using Xenon Arc (Weekers et al., 1961).
Backman and colleagues used Ruby Laser in 1972 (Beckman
et al., 1972). Moreover, Frakhauser and associate, incorpo-
rated a thermal mode into a Neodymium:YAG Laser System
to perform transscleral CPC (Frankhauser and Kwasniewska,
1993).
Semiconductor diode laser (wave length of 809 nm) can
effectively reduce IOP with potential advantage over YAG
of greater melanin absorption (Peyman et al., 1990; Assia
et al., 1991; Brancato et al., 1991). Meanwhile, diode laser re-
quires less energy for achieving gross and histological changes
in the ciliary body.
In our study we use a controlled transscleral by ﬁxed power
and ﬁxed duration.Etiology of glaucoma Number Percentage (%)
Open angle type 9 25.7
Closed angle type 12 34.3
Congenital glaucoma 8 22.9
Ghost cell glaucoma 1 2.9
Combined mechanism glaucoma 1 2.9
Neovascular glaucoma 4 11.4
Total 35 1002. Patients and methods
Thirty two consecutive patients with refractory glaucoma (35
eyes) were prospectively enrolled in the current study. Out of
the recruited patients; 26 (74.3%) were females and six
(25.7%) were males while three female patients were bilaterally
operated. All patients underwent transscleral contact con-
trolled procedure.The inclusion criteria were; presence of uncontrolled glau-
coma on maximum tolerated anti-glaucoma medications
and/or failed previous glaucoma surgery. Nevertheless, the
exclusion criteria were presenting cases with history of prior la-
ser cyclodestructive therapy.
Demographic data including; age, sex, pre and postopera-
tive medications were collected. All patients went through
the following ophthalmic examination; Best-corrected Snellen
Visual Acuity (BCVA), Slit Lamp examination, IOP measured
using Goldman Applanation Tonometry and Tono-pen in
pediatric group. Different types of glaucoma etiologies were
presenting in our study as demonstrated in (Table 1). This in-
cludes; 12 (34.3%) eyes with angle closure type, nine (25.7%)
eyes with open angle glaucoma, eight (22.9%) eyes with con-
genital glaucoma, four (11.4) eyes with neovascular glaucoma,
one (2.9%) with ghost cell type and one (2.9%) with combined
mechanism. The mean (±SD) of age of the sample was 50
(±27), (range: 3 M – 72 years), VA ranges between NLP –
20/80, the mean (±SD) preoperative IOP was 35.1 (±10.7)
(range 15–56 mm Hg) while the mean number of anti-glau-
coma medications was three (range 1–4 medications).
Previous surgical procedures were done to 25 eyes (Table
2); seven (28%) of open angle glaucoma, six (24%) of chronic
angle closure glaucoma, one (4%) of neovascular glaucoma,
one (4%) of ghost cell glaucoma, and 10 (40%) of congenital
glaucoma. Ten eyes were not operated, seven (70%) eyes had
NLP and three (30%) were seeing eyes (Table 3).
All adult patients were operated under peribulber local
anesthesia. General anesthesia was used in a pediatric group
for the convenience of operation. Preoperative cycloplegic
and mydriatic drops were applied to all patients, then they
were exposed to a single treatment of diode laser (809 nm),
four shots in each quadrant. Thus, a total of 16 shots were gi-
ven using a ﬁber optic prop 1.5 mm, from the limbus with the
help of transilluminator. Power of 5 W in adult group and 3 W
in pediatric group, with a duration of 0.5 s.
Postoperative topical atropine and steroid drops as well as
anti glaucoma medications were applied to patients. The mean
follow up was of M (±SD) 80.23±9.5 (range: 36–84 months).
Our outcome measurement indicators were mainly; change in
pre and post IOP and the number of utilized medication.
Figure 1 Intraocular Pressure at different visits and postoper-
ative ﬁnal IOP.
Table 2 Patients with previous surgical procedures.
Types Previous surgical procedures Number Percentage (%)
Open angle types Trabeculectomy with MMC 3 12
ECCE and IOL 3 12
Trabeculectomy with ECCE and PCIOL 1 4
Chronic angle closure glaucoma ECCE–PCIOL 2 8
Trabeculectomy with ECCE and PCIOL 1 4
Trabeculectomy with MMC 3 12
NVG (neovascular glaucoma) PPV (Parsplana Vitrectomy) 1 4
Ghost cell glaucoma PPV (Parsplana Vitrectomy) 1 4
Congenital glaucoma Trabeculotomy and trabeculectomy (combined) 7 28
Trabeculectomy and tube surgery 1 4
Deepsclerectomy and combined procedure 1 4
Tube surgery and combined procedure 1 4
Total 25 100
Table 3 Eyes with no previous surgery.
VA NVG OAG CACG
NLP 2 2 3
LP 1
HM 1
20/80 1
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6 months and at the ﬁnal visit. T test to evaluate statistical sig-
niﬁcance of mean differences between preoperative and post-
operative IOPs in the ﬁnal visit were evaluated, differences
between preoperative and postoperative VA. The number of
anti-glaucoma medication taken before and after surgery was
also investigated using Wilcoxon Signed Rank test for non-
parametric categorical data.
The criteria of outcome of interest were as follows;
Complete success: if IOP 6 22 mm Hg without any glau-
coma medication.
Qualiﬁed success: if IOPP 22 mm Hg with glaucoma
medication(s).
Complete failure: if IOP > 22 mm Hg & require further
surgical intervention to control IOP.3. Results
Thirty ﬁve eyes were enrolled in this study, out of which 30
(85.7%) eyes were females and ﬁve (14.3%) were males. The
mean (SD) IOP before surgery was 35.1(±10.74) (range 15–
56 mm Hg) compared to postoperative values of 18.8(±7.29)
(range 6–40) Fig. 1. Preoperative Visual Acuity ranged from
NLP to (20/80), M (±SD) Postoperative Visual Acuity ranged
from NLP to 20/60. Snellen Log Mar pre-surgical Visual Acu-
ity M (±SD) was 2.6 (±1.1), while it was 24.5 (±101.3) post
surgery. Visual Acuity improved in three eyes (8.5%), did not
change in 27 eyes (77.1%) and decreased in ﬁve eyes (14.2%).
Fig. 2. The mean number of anti-glaucoma medications re-
duced from 2.8±0.83 (range 3–4) to 1.71 ± 1.10 (range 0–3)post treatment P value <0.0001 which is statistically
signiﬁcant.
In the ﬁrst 2 weeks, the mean IOP was 22.97 ± 10.83, which
was about 35% reduction to the mean preoperative IOP
(35.09 ± 10.74). This reduction was found to be statistically
signiﬁcant (t: 9.8 [95% CI: 12.93–19.69], P< 0.001).The mean
IOP at three months was 26.23 ± 8.68 mm Hg which was
about 22% reduction to the mean preoperative IOP. The mean
IOP at six months was 21.26 ± 7.72 mm Hg which was about a
37% reduction to the preoperative IOP.
At the ﬁnal follow up visit, the mean IOP was M (±SD)
18.77 ± 7.29 mm Hg, which was a 16.33% reduction to the
preoperative IOP. According to criteria of treatment outcome
for IOP control, complete success was achieved in seven eyes
(20%), 22 eyes (62.8%) showed qualiﬁed successes and com-
plete failure was reported in six eyes (17.1%) while the overall
success rate in 29 eyes was (82.8%).
Among our patients there were eight eyes of congenital
glaucoma with a history of previous glaucoma surgeries. Four
eyes were controlled after COCO without medication (50%
Table 4 Postoperative short complications.
Complication Number Percentage (%)
Pain 2 14.3
Subconjunctival hemorrhage 2 14.3
Corneal epithelial defect 2 14.3
AC reaction 8 57.1
Choroidal 0 N/A
Visual loss 0 N/A
Phthisis bulbi 0 N/A
Sympathetic ophthalmia 0 N/A
Figure 2 Comparison of pre- and postoperative visual acuity.
NLP: no light perception, LP: light perception, FL: follow light.
12 E.A. Osman et al.complete success) and four other eyes showed qualiﬁed success
according to our previously mentioned criteria. Postoperative
mean IOP was reduced to 16.62 ± 4.06 (range 16–21 mm Hg)
compared to a preoperative mean IOP of 25.37 ± 7.02 (range
15–35 mm Hg). Postoperative short term complications
showed pain in two (5.7%) eyes during the procedure, eight
(22.9%) eyes developed postoperative mild anterior chamber
reaction and two (5.7%) eyes developed subconjunctival hem-
orrhage (Table 4). No eyes developed choroidal detachment,
phthisis bulbi, or sympathetic ophthalmia till the end of follow
up.4. Discussion
Cyclodestructive procedure has been used to control IOP for
many years (Bietti, 1950). Diathermy and cryotherapy are
associated with complications including loss of vision and
phthisis bulbi (Liu et al., 1994; de Roeth, 1986; Bellows and
Grant, 1978; Mc Lean and Lincoff, 1964). The development
of YAG, Ruby, and Krypton lasers have been used for many
years with less side effects (Beckman et al., 1972; Schuman
et al., 1990, 1992; Aubry et al., 1994; Seah et al., 1994).YAG laser showed whitening and contraction of ciliary
body epithelium however, diode laser produces less blanching,
deeper ciliary body contraction and coagulation.
Semiconductor diode laser (805–810 nm) is effective as it is
more absorbed by melanin pigment in the ciliary body. The
mechanisms of decreasing IOP by diode laser, include; destruc-
tion of ciliary epithelium, ciliary body atrophy, decrease ciliary
body vasculature, increase uveoscleral outﬂow and decrease
ciliary body epithelial surface.
In transscleral cyclophotocoagulation (CPC) the surgeon
cannot directly observe the effects of the applied laser. Over
dosage, may result in unwanted pop effects, or under dosage
with no therapeutic effect which often occur contrary in con-
trolled COCO. Laser radiation passing through the sclera
and ciliary body is partly reﬂected from the fundus and can
be monitored from outside the eye by a detector system, since
all other parameters inﬂuencing the intensity of the recorded
radiation are constant in time during one laser exposure, The
time dependence of this radiation directly reﬂects the change
of transmission of the treated tissue. The laser exposure there-
fore, can be stopped by computer, when certain criteria of the
recorded curves are fulﬁlled.
COCO machine needs a special calibration before using it,
followed by setting the power and transilluminator to deﬁne
the exact site of ciliary body, application of laser 1.5 mm from
limbus and three mm from limbus which may enhance the
uveoscleral outﬂow according to Liu et al. (1994).5. Compared to other studies
Very few studies of COCO procedures had been published
Augstin et al reported that there was no case of severe compli-
cations and that reduction of risk may allow broader applica-
tion of the method (Augustin et al., 1998). Jochen Wahl et al.
recommended the procedure to be taken into account as a pri-
mary intervention because of low complication rates and good
pressure reducing effect (Wahl and Preussner, 2002). More-
over, Preubner demonstrated results of more than 10 years
of application experience with no observed complications
including no phthisis bulbi in addition to a range of pressure
reduction of (20–25%) (Preubner, 2008).
Compared to other cyclodestructive procedures; Carprioli
has reported 70% visual loss in cyclocryotherapy (Carprioli
et al., 1985), Krupin reported 34% phthisis bulbi (Krupin
et al., 1978) while Shields reported up to 46.6% visual loss in
cyclophotocoagulation (Shields and Shields, 1994).
In a recent study by Nitza Coben; 32 patients who under-
went diode Cyclophotocoagulation results demonstrate con-
trolled IOP in 62.5%, two eyes of visual loss and one eye
with phthisis bulbi (Goldenberg and Bahar, 2005).
In our study the majority of cases did not show signiﬁcant
changes of VA (77.1%) and no patients lost their visual acuity
from seeing eyes. As regards to the eight cases with previous
history of congenital glaucoma, four eyes had controlled IOP
without medication (complete success = 50%) and the other
four were controlled with medication (qualiﬁed suc-
cess = 50%), which gives an overall success rate of 100%.
We conclude that COCO procedure increases the precision
and safety of trans-scleral cyclophotocoagulation (Preubner
et al., 1997), it is a simple procedure, non-penetrating and
with minimal side effects. It is recommended to be used in
Controlled Cyclophotocoagulation with diode laser in refractory glaucoma 13seeing eyes. It also reduces the number of anti-glaucoma med-
ications. With COCO procedure to the best of our knowledge,
patients do not develop phthisis bulbi or sympathetic ophthal-
mia as feared complications.Disclaimer
No ﬁnancial or proprietary interest in any aspect of this study.References
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